Market News How it works Learn FAQ
| RCT 0.0923 21.29% | NU 12.5021 -17.53% | EWZ 34.02 -20.12% | BBD 2.877 -29.31% | TGL 0.2429 9.66% | AZTR 2.05 186.71% | ITUB 7.68 -20.58% | SRTM 0.2775 -35.51% | NVD 3.995 -4.65% | XP 15.4801 -49.10% | WFF 0.089 11.25% | SHFS 0.091 -31.27% | SPCX 149.37 1.27% | SOXL 92.37 10.54% | PBR 22.715 -13.17% | VALE 11.99 -3.31% | CLRO 4.84 48.92% | INTC 91.75 5.51% | GCDT 0.1443 -18.06% | TSLL 10.885 11.53% | NWGL 0.0872 6.34% | NOK 8.715 7.06% | NVDA 216.1126 2.44% | SOXS 46.95 -10.50% | CRWV 56.22 3.66% | BITO 10.695 -1.25% | RWM 14.475 -0.52% | GPUS 0.1858 10.01% | SGRY 23.185 47.21% | TSLG 5.445 11.81% | ABEV 2.805 -15.00% | JBLU 2.285 -12.95% | IREN 26.025 4.50% | INTR 4.595 -36.09% | RBNE 0.1682 -11.47% | QID 14.1701 -2.61% | AAL 12.1792 0.57% | TQQQ 68.8286 3.83% | SBS 4.6303 -27.65% | SPDN 8.485 -0.64% | TSLA 393.84 5.81% | T 20.6998 -1.10% | LUCD 0.538 30.90% | SID 0.9075 -23.09% | WULF 12.3201 8.83% | XTND 2.2899 29.37% | NFLX 63.005 -4.32% | CIFR 7.885 -0.69% | SQQQ 38.17 -3.81% | RIG 6.555 2.26%
SLSELLAS Life Sciences Group, Inc. logo

SELLAS Life Sciences Group, Inc. (SLS)

NASDAQ · Currency in USD
$11.35 ▼ -0.19 (-1.62%)
As of Oct 26, 3:24 PM ET. Market open.

Summary

Previous Close
$11.54
Open
$11.50
Day's Range
$11.18 – $11.70
52 Week Range
$1.39 – $15.88
Volume
2,338,404
Avg. Volume
7,648,720
Market Cap
$2.29B
Beta (5Y Monthly)
2.57
PE Ratio (TTM)
--
EPS (TTM)
-$0.17
Earnings Date
Nov 18, 2026
Forward Dividend & Yield
--
Ex-Dividend Date
--
1y Target Est
$35.00

Profile: SELLAS Life Sciences Group, Inc.

Sector
Healthcare
Industry
Biotechnology
Full-time employees
13
CEO
Angelos Stergiou

SELLAS Life Sciences Group, Inc., a late-stage clinical biopharmaceutical company, focuses on the development of novel therapeutics for various cancer indications in the United States. The company's lead product candidate is galinpepimut-S (GPS), a peptide immunotherapy directed against the Wilms tumor 1, antigen; and SLS009 (tambiciclib), a selective small molecule cyclin-dependent kinase 9, or CDK9, inhibitor. It has a strategic collaboration with Merck & Co., Inc. to evaluate GPS as it is administered in combination with PD1 blocker pembrolizumab in a Phase 1/2 clinical trial enrolling patients in up to five cancer indications, including hematologic malignancies and solid tumors; GenFleet Therapeutics (Shanghai), Inc. for the development and commercialization of GFH009; and Memorial Sloan Kettering Cancer Center for developing and commercializing MSK's WT1 peptide vaccine technology.

Earnings

Next report: Wed, Nov 18, 2026
EPS estimate -$0.05
DateEst.Actual
Aug 11, 2026-$0.05-$0.05Miss
May 12, 2026-$0.06-$0.05Beat
Mar 19, 2026-$0.06-$0.05Beat
Nov 12, 2025-$0.06-$0.06Beat
Aug 12, 2025-$0.08-$0.07Beat
May 13, 2025-$0.10-$0.07Beat

Analyst view

Consensus price target
$35.00 ▲ +208.3%
Range $35.00 – $35.00
Rating: Buy
Buy 100% · Hold 0% · Sell 0%

Get free alerts on SLS and big market moves

Free special alerts by text & email on new investment opportunities, buyouts and the stocks moving most, in plain English.
Get free stock alerts →
Data: Financial Modeling Prep. For information only, not investment advice.